Cargando…

Real-time methylation-specific PCR for the evaluation of methylation status of MGMT gene in glioblastoma

The methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) gene is a strong predictor for the efficacy of temozolomide chemotherapy and survival periods. However, the correlation between the extent of methylation and the difference in survival times has not been fully clarified. Sim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshioka, Masaki, Matsutani, Tomoo, Hara, Ayaka, Hirono, Seiichiro, Hiwasa, Takaki, Takiguchi, Masaki, Iwadate, Yasuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021237/ https://www.ncbi.nlm.nih.gov/pubmed/29963232 http://dx.doi.org/10.18632/oncotarget.25543

Ejemplares similares

Role of Evaluating MGMT Status and 1p36 Deletion in Radiosurgery-Induced Anaplastic Ependymoma That Rapidly and Completely Resolved by Temozolomide Alone: Case Report and Review of the Literature
por: Hirono, Seiichiro, et al.
Publicado: (2015)

NQPC-05 BEVACIZUMAB AFTER PROGRESSION OF GLIOBLASTOMA PROLONGS PATIENT’S LIVING TIME AT HOME IN THE LAST 90 DAYS
por: Matsutani, Tomoo, et al.
Publicado: (2019)

Autologous antibody to src-homology 3-domain GRB2-like 1 specifically increases in the sera of patients with low-grade gliomas
por: Matsutani, Tomoo, et al.
Publicado: (2012)

STMO-11 Supratotal resection of Glioblastoma with Methionine PET
por: Ko, Ozaki, et al.
Publicado: (2020)

Oncological and functional outcomes of supratotal resection of IDH1 wild-type glioblastoma based on (11)C-methionine PET: a retrospective, single-center study
por: Hirono, Seiichiro, et al.
Publicado: (2021)

STMO-3 Mid- to long-term outcome of supratotal resection of IDH1 wild-type glioblastoma based on 11C-methionine PET: a retrospective, single-center study
por: Hirono, Seiichiro, et al.
Publicado: (2021)

Circulating anti-filamin C autoantibody as a potential serum biomarker for low-grade gliomas
por: Adachi-Hayama, Masayo, et al.
Publicado: (2014)

STMO-05 SURGICAL AND FUNCTIONAL OUTCOME OF AWAKE SURGERY FOR INSULAR GLIOMA
por: Hirono, Seiichiro, et al.
Publicado: (2019)

STMO-13 PATHOLOGICAL EVALUATION AND ONCOLOGICAL OUTCOME OF FLAIRECTOMY IN PATIENTS WITH IDH1 WILD-TYPE GLIOBLASTOMA
por: Hirono, Seiichiro, et al.
Publicado: (2022)

Elevation of Autoantibody in Patients with Ischemic Stroke
por: YOSHIDA, Yoichi, et al.
Publicado: (2018)

CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy
por: Hara, Ayaka, et al.
Publicado: (2020)

MGMT Methylation Status: The Advent of Stratified Therapy in Glioblastoma?
por: Hau, Peter, et al.
Publicado: (2007)

Association between MGMT Enhancer Methylation and MGMT Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma
por: Zappe, Katja, et al.
Publicado: (2023)

Personalized treatment strategies in glioblastoma: MGMT promoter methylation status
por: Thon, Niklas, et al.
Publicado: (2013)

Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients
por: Estival, Anna, et al.
Publicado: (2019)

An evaluation of MGMT promoter methylation within the methylation subclasses of glioblastoma
por: Alnahhas, Iyad, et al.
Publicado: (2020)

MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas
por: Korfiatis, Panagiotis, et al.
Publicado: (2016)

Tim-3 Expression and MGMT Methylation Status Association With Survival in Glioblastoma
por: Zhang, Ji, et al.
Publicado: (2020)

Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma
por: Nguyen, Ngan, et al.
Publicado: (2021)

Peritumoral ADC Values Correlate with the MGMT Methylation Status in Patients with Glioblastoma
por: Ladenhauf, Valentin Karl, et al.
Publicado: (2023)

MGMT promoter methylation in Peruvian patients with glioblastoma
por: Belmar-Lopez, Carolina, et al.
Publicado: (2018)

GCT-09. HEALTH AND SOCIAL ISSUES IN THE LONG-TERM GERM-CELL TUMOR SURVIVORS
por: Matsutani, Tomoo, et al.
Publicado: (2020)

Radiomics and MGMT promoter methylation for prognostication of newly diagnosed glioblastoma
por: Sasaki, Takahiro, et al.
Publicado: (2019)

MPC-8 Serum anti-zinc finger FYVE domain-containing protein 21 (ZFYVE21) autoantibody as a novel biomarker for oligodendroglioma IDH-mutant and 1p/19q co-deletion
por: Matsutani, Tomoo, et al.
Publicado: (2021)

Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma
por: Uno, Miyuki, et al.
Publicado: (2011)

Influence of Intratumor Heterogeneity on the Predictivity of MGMT Gene Promoter Methylation Status in Glioblastoma
por: Brigliadori, Giovanni, et al.
Publicado: (2020)

Quantitative Analysis of the MGMT Methylation Status of Glioblastomas in Light of the 2021 WHO Classification
por: Häni, Levin, et al.
Publicado: (2022)

Serum anti-SERPINE1 antibody as a potential biomarker of acute cerebral infarction
por: Kubota, Masaaki, et al.
Publicado: (2021)

PATH-03. HIGH-GRADE NEUROEPITHELIAL TUMOR SHOWING BCOR IMMUNOPOSITIVITY WITHOUT EXON 15 INTERNAL TANDEM DUPLICATIONS IN A FIVE-YEAR-OLD BOY: A CASE REPORT
por: Wakita, Shogo, et al.
Publicado: (2020)

MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR
por: Håvik, Annette Bentsen, et al.
Publicado: (2012)

Identification of stroke-associated-antigens via screening of recombinant proteins from the human expression cDNA library (SEREX)
por: Machida, Toshio, et al.
Publicado: (2015)

Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region
por: Kanemoto, Manabu, et al.
Publicado: (2014)

Prognostic Role of Methylation Status of the MGMT Promoter Determined Quantitatively by Pyrosequencing in Glioblastoma Patients
por: Kim, Dae Cheol, et al.
Publicado: (2016)

Prognosis of Glioblastoma With Oligodendroglioma Component is Associated With the IDH1 Mutation and MGMT Methylation Status()
por: Myung, Jae Kyung, et al.
Publicado: (2014)

XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype Glioblastoma
por: Le, Nguyen Quoc Khanh, et al.
Publicado: (2020)

The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status
por: Chen, Wei-jun, et al.
Publicado: (2020)

CS-1 Cerebellar liponeurocytoma; Report of two cases with detailed metabolic, immunohistochemical, and genetic evaluations
por: Shimizu, Miyuki, et al.
Publicado: (2021)

Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation
por: Kim, Se-Hyuk, et al.
Publicado: (2018)

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
por: Melguizo, Consolación, et al.
Publicado: (2012)

Assessment of MGMT methylation status using high-performance liquid chromatography in newly diagnosed glioblastoma
por: Hanihara, Mitsuto, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9p94g379hvqkirpoc37a8msm8v